Protara Therapeutics (TARA) said late Monday it has closed an underwritten public offering of about 13 million shares at $5.75 per share, for gross proceeds of roughly $75 million.

Underwriters were given a 30-day option to buy up to about 1.96 million additional shares, the company said.

Net proceeds will be used for its clinical programs, working capital and general corporate purposes, the clinical-stage company said.